SunGen Pharma, a specialty pharma company, has entered into a Manufacturing Agreement with Grand River Aseptic Manufacturing (GRAM) to manufacture generic injectable pharmaceutical products.

“We are excited to work with GRAM on the manufacturing of these important injectable products, and are pleased to announce that we have successfully filed an injectable ANDA manufactured by GRAM. It is an antispasmodic and anticholinergic agent.  We expect our next ANDA manufactured by GRAM to be filed with U.S. FDA by the end of 2019. The product is used in combination chemotherapy,” said Dr. Isaac Liu, Co- chief executive officer of SunGen Pharma, “SunGen continues to build a strong pipeline by combining our own products and those co-developed with partners around the world.”

SunGen Pharma launched its first injectable product in August 2017.  The company expanded its injectable division in October 2017 through the acquisition of a privately held pharmaceutical company based in Monmouth Junction, NJ. It currently has more than thirty products in its pipeline, and it has more than fifteen co development, manufacturing and marketing partners in North America, Europe and Asia.   

“The relationship between SunGen and GRAM has been very productive and the companies continue working on additional products for future filings.  We are excited to support SunGen’s efforts to fill specific needs in the pharmaceutical marketplace,” said Thomas Ross, chief executive officer of GRAM.